Skip to main content

GH Research PLC

GHRS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001855129

No open-market purchases or sales by GH Research PLC insiders were filed in the last 90 days; 63 institutions reported holding it in 13F filings for Q2 2026, worth $1.38B in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding GH Research PLC changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of GHRS: Q3 2022 compared with Q4 2022
MeasureQ3 2022Of which not filed for Q4 2022Q4 2022Change
Holders34132−1
Shares31.6M10.0K30.9M−696.5K (−2.2%)
Value$367.2M$116.2K$299.5M−$67.6M (−18.4%)

1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (2)

Institutions that held GH Research PLC at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to GHRS in Q4 2022
InstitutionSharesValue% of portfolio
Cornerstone Investment Partners, LLC14,800$143.9K0.01%
Cubist Systematic Strategies, LLC700$6.80K0.00%

Sold out (3)

Institutions that held GH Research PLC at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of GHRS in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
TimesSquare Capital Management, LLC463,600$5.39M
DAFNA Capital Management LLC52,631$612.0K
Virtus ETF Advisers LLC10,026$117.0K

Not filed for Q4 2022 yet (1)

Institutions that held GH Research PLC at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding GHRS in Q3 2022 that haven't filed for Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Jefferies Group LLC10,000$116.2K